Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees.  The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. The company is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The company operates in more than 35 countries worldwide.

Gilead Sciences, Inc. adalah perusahaan biofarmasi yang terlibat dalam penelitian, pengembangan, dan komersialisasi obat-obatan di area kebutuhan medis yang belum terpenuhi. Perusahaan ini berkantor pusat di Foster City, California, dan saat ini mempekerjakan 17.600 karyawan penuh waktu. Perusahaan ini berfokus pada pengembangan obat-obatan untuk mencegah dan mengobati penyakit yang mengancam jiwa, termasuk virus imunodefisiensi manusia (HIV), hepatitis virus, COVID-19, kanker, dan peradangan. Perusahaan ini berorientasi pada penemuan, pengembangan, dan penyampaian obat untuk memenuhi kebutuhan medis yang belum terpenuhi di virologi, onkologi, dan area terapeutik lainnya. Portofolio produk yang dipasarkan mencakup Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, dan Letairis. Kandidat produk perusahaan mencakup Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, dan Domvanalimab serta zimberelimab. Biktarvy adalah formulasi oral yang diberikan sekali sehari untuk pengobatan infeksi HIV-1 pada pasien tertentu. Perusahaan ini beroperasi di lebih dari 35 negara di seluruh dunia.

Gilead Sciences

NVIDIA

Apple

Google

Microsoft

Amazon

Broadcom

Meta Platforms

Taiwan Semiconductor

Tesla

Berkshire Hathaway

Walmart

Eli Lilly

JPMorgan

Visa

Oracle

Exxon Mobil

MasterCard

Johnson & Johnson

Netflix

ASML

SPDR S&P500 ETF

Palantir

AbbVie

Bank of America

Costco

Alibaba

Home Depot

Procter & Gamble

General Electric

Cisco

Chevron

Vanguard Total Stock Market ETF

UnitedHealth Group

Coca-Cola

Wells Fargo

Morgan Stanley

Caterpillar

AstraZeneca

Goldman Sachs

Toyota

American Express

Micron Technology

Novartis

Merck

Salesforce

T-Mobile

Philip Morris

Raytheon Technologies

Royal Bank of Canada

McDonald's

Abbott

Applied Materials

Novo Nordisk

Shell

Shopify

Intuitive Surgical

Invesco QQQ Trust

PepsiCo

Citigroup

Lam Research

Intel

Uber

Disney

Linde PLC

QUALCOMM

Blackstone

Intuit

Amgen

AT&T

ServiceNow

Verizon

NextEra Energy

Charles Schwab

Sony

BlackRock

Accenture

Texas Instruments

Booking Holdings

Danaher

Banco Santander

Arista Networks

Boeing

S&P Global

Toronto-Dominion Bank

Capital One

Pfizer

Unilever

Boston Scientific

TotalEnergies

Union Pacific

Adobe

Lowe's

Palo Alto Networks

Gilead Sciences Stock

About Gilead Sciences

Key Statistics